The combination of CTLA-4 blockade and vaccination with B16 or SM1 cells, genetically modified to express GM-CSF, showed enhanced efficacy and tumor regression when administered in a B16 melanoma model and SM1 mammary carcinoma model, respectively. The gene discussed is CTLA4; the disease is melanoma.